Capital Fund Management (CFM)
MYGN icon

Capital Fund Management (CFM)’s Myriad Genetics MYGN Stock Holding History

Capital Fund Management (CFM)’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-26,900
Closed -$924K – 2062
2017
Q4 		$924K Buy
+26,900
New +$908K 0.01% 1251
2013
Q3 		– Sell
-41,100
Closed -$1.1M – 1786
2013
Q2 		$1.1M Buy
+41,100
New +$1.19M 0.02% 779

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Capital Fund Management (CFM)'s MYGN Position: Q2 2025 in Review

Capital Fund Management (CFM) sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 44,917 shares — an estimated $398K sold.

Capital Fund Management (CFM) first reported a position in MYGN in Q4 2013 and held it in 7 quarters. The position peaked at $2.94M in Q2 2016. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Capital Fund Management (CFM) reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 44,917 Myriad Genetics shares in Q2 2025, an estimated $398K.
  • Capital Fund Management (CFM) first reported a position in Myriad Genetics in Q4 2013 and held it in 7 quarters.
  • Capital Fund Management (CFM)'s Myriad Genetics position peaked at $2.94M in Q2 2016.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2025, filed 13 Aug 2025.